Timing note: Charles River Laboratories is scheduled to report today, Wednesday, August 5, 2026, before the market opens—not tomorrow—with the earnings call at 9:00 a.m. ET. (ir.criver.com)
This quarter is primarily a test of margin execution and forward demand, rather than reported revenue growth. The divestitures completed during Q2 will create a sizable reported-revenue decline, so investors should focus on:
CRL has already rebounded sharply from its May lows, increasing the hurdle for a favorable reaction. A modest EPS beat may not be enough without healthy bookings and credible second-half guidance.
| Metric | 2026Q2 consensus | Comparison |
|---|---|---|
| Revenue | $974.7 million | Down approximately 5.6% from $1.03 billion in 2025Q2 |
| Adjusted EPS | $2.73 | Up approximately 33% sequentially; down 12.5% year over year |
| EBIT | $205.0 million | Implies an approximately 21% margin |
| FY2026 revenue | $3.85 billion | Approximately 4.1% below 2025 |
| FY2026 adjusted EPS | $11.11 | Near the upper half of company guidance |
Consensus ranges are $954.7 million–$1.02 billion for revenue and $2.68–$2.91 for adjusted EPS. (charlesriverlaboratories.gcs-web.com)
Management previously guided to:
Thus, the $2.73 EPS consensus is only modestly above management’s implied Q2 floor. The more demanding question is whether CRL remains on pace for a much stronger second half.
DSA is CRL’s largest segment and the principal driver of the investment case. In Q1, DSA organic revenue declined 1.4%, while its adjusted margin fell to 21.0% because of higher large-model sourcing and study-start costs. (ir.criver.com)
The leading indicators were more constructive:
Management expected this momentum to return DSA to organic growth during the second half. The most important Q2 disclosures will therefore be:
A small quarterly revenue miss accompanied by strong bookings could be tolerated. An EPS beat accompanied by weaker bookings would be lower quality.
Q1’s adjusted operating margin was only 16.3%, down from 19.1%, due to NHP-related DSA costs, unfavorable RMS mix and executive-transition compensation. CRL said these headwinds would subside in Q2 and that all three segments should improve sequentially. (ir.criver.com)
Consensus EBIT implies an adjusted margin of roughly 21%, or nearly 475 basis points above Q1. That is the clearest quantitative hurdle for the quarter.
CRL should begin benefiting from lower study-start costs and greater internal sourcing of non-human primates following its K.F. Cambodia and Noveprim investments. The largest DSA improvement was previously expected later in the year, particularly Q4, so investors should not require full normalization in Q2. They should require a visible step in that direction.
The May 6 divestiture of the lower-margin CDMO and Cell Solutions operations should materially improve the remaining segment’s mix. The continuing Microbial Solutions and Biologics Testing businesses have historically generated margins above 30%.
A Manufacturing margin that remains materially below 30%, absent a clear timing explanation, would raise questions about the supposed structural benefit of the divestiture.
RMS should benefit from a recovery in NHP shipment timing after Q1 weakness. Offsetting that are soft North American small-model demand, academic and government uncertainty, and weak demand from start-up biotech customers using CRL’s flexible-vivarium offering.
The key question is whether Q1’s 5.5% organic decline represented a trough or continuing structural pressure.
CRL completed the CDMO and Cell Solutions sale on May 6 and the sale of certain European Discovery Services sites later in May. These transactions were expected to subtract roughly five percentage points from 2026 reported growth while improving margins and sharpening the company’s focus on regulated testing. (ir.criver.com)
Consequently:
The strategic direction—simpler portfolio, higher margins and greater focus on regulated services—is sensible. Q2 is the first opportunity to see whether the financial benefits match the narrative.
The FY2026 adjusted EPS consensus of $11.11 sits above the $11.05 midpoint of company guidance. After Q1 actual EPS of $2.06 and Q2 consensus of $2.73, CRL would need approximately $6.26 combined in Q3 and Q4 merely to reach the guidance midpoint.
That back-half requirement rests on:
A simple reaffirmation would be acceptable if bookings and margin trends improve. However, the strongest outcome would be a narrowing toward the upper half or a modest raise. A guidance cut—or less confidence in the expected 500-basis-point second-half versus first-half margin improvement—would undermine the central earnings thesis.
CRL continues to guide to $375 million–$400 million of 2026 free cash flow. It repurchased $200 million of shares in Q1 and had $800 million remaining on its authorization, but net leverage was 2.6x after acquisitions and buybacks. (ir.criver.com)
Investors should listen for:
Debt reduction would probably be the more prudent near-term use of cash unless the stock becomes materially cheaper.
The headline EPS hurdle is relatively manageable; the bookings and margin hurdles are not. Q2 consensus already reflects management’s promised sequential EPS recovery, while the current valuation assumes the portfolio restructuring will produce materially better second-half earnings.
The best evidence supporting that thesis would be DSA book-to-bill above 1.0x, sequential margin improvement across all three segments and unwavering confidence in the second-half ramp. Without those elements, even an EPS beat could prove insufficient.